Eli Lilly Warns of Safety Risks with Compounded Tirzepatide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy LLY?
Source: seekingalpha
- Safety Risk Warning: Eli Lilly has issued a warning regarding compounded tirzepatide mixed with vitamin B12, revealing significant levels of impurities that could lead to toxicity and immune reactions, thus alerting patients to the potential dangers of using such products.
- FDA Recall Request: The company urged the FDA to recall all compounded tirzepatide products mixed with untested additives, emphasizing its commitment to consumer safety and the need to mitigate unknown risks associated with these medications.
- Competitive Market Pressure: Eli Lilly faces pressure from cheaper copycat versions of its drugs that bypass strict regulatory approval processes, despite the FDA declaring that the supply shortage has been resolved, meaning compounded medications are no longer permitted.
- Industry Dynamics Shift: Hims & Hers has entered into an agreement with Novo Nordisk to discontinue its compounded GLP-1 products in favor of Novo's weight-loss drugs, indicating a growing market preference for compliant products over unregulated alternatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1006.700
Low
950.00
Averages
1192
High
1500
Current: 1006.700
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Aims to Close Gap with Eli Lilly in Weight-Loss Market
- Intensifying Market Competition: Despite Novo Nordisk's first-mover advantage in the weight-loss drug market, Eli Lilly's Zepbound saw an 80% year-over-year sales increase, threatening Novo's market position and prompting the launch of an oral version of Wegovy to cater to patient preferences for oral treatments, thereby enhancing its competitive stance.
- New Drug Development Updates: Eli Lilly launched its own weight-loss pill, Foundayo, in April and is developing a triple agonist, retatrutide, targeting GLP-1, GIP, and glucagon receptors, which could further solidify its market dominance and increase pressure on Novo Nordisk.
- Clinical Trial Results: Eli Lilly's promising phase 3 clinical trial data for retatrutide, released in March, showed significant reductions in A1C and weight loss among participants, establishing a strong foundation for its future market performance and potentially keeping its stock elevated.
- Market Valuation Outlook: Although Eli Lilly's stock trades above $1,000 with a price-to-earnings ratio exceeding 26, if its follow-up products maintain market superiority, investors will likely continue to view it as a top GLP-1 stock, supporting its premium valuation.
See More
Wall Street's Stock Analysis Highlights
- Sell Recommendation for Shutterstock: Shutterstock (SSTK) faces a projected 13.7% sales decline over the next 12 months, with average customer spending down by 87.9%, indicating a challenging demand environment; its earnings per share have fallen by 6.3% annually over the last three years, despite revenue growth, highlighting significantly lower profitability of incremental sales.
- Brookdale's Performance Issues: Brookdale (BKD) has seen flat sales over the past five years, with a projected 4.4% sales drop in the next 12 months; a high net-debt-to-EBITDA ratio of 11x could force the company to raise capital under unfavorable terms if market conditions worsen, with its current stock price at $12.98 and an EV/EBITDA ratio of 15.8.
- Buy Recommendation for Eli Lilly: Eli Lilly (LLY) has achieved an impressive 41.8% annual revenue growth over the past two years, reflecting significant market share gains, while adjusted operating profits and efficiency have improved, and share repurchases have amplified shareholder returns with a 29.6% growth in earnings per share, trading at $990.36 per share with a forward P/E of 26.1.
- Market Sentiment Analysis: While Wall Street's bullish forecasts for several stocks may be overly optimistic, Eli Lilly's strong fundamentals and growth potential position it as a worthy investment, reflecting the market's focus on high-quality companies.
See More
Eli Lilly Provides Community Courts to Indianapolis for 150th Anniversary
- Community Courts Opening: Eli Lilly, in partnership with the Caitlin Clark Foundation, has opened three multi-sport community courts in Indianapolis, aimed at providing safe, high-quality spaces for youth to engage in sports, thereby enhancing community health and vitality.
- Anniversary Contribution: As part of its 150th anniversary celebration, Lilly is providing a park and court at the corner of E. South Street and S. New Jersey Street to the City of Indianapolis and Indy Parks, further solidifying its long-standing connection with the community.
- Facility Design and Features: The newly constructed courts utilize the Musco Mini-Pitch system, designed for basketball, soccer, and futsal, equipped with lighting and ADA-accessible features, ensuring flexible and inclusive spaces for a diverse range of users.
- Long-term Community Impact: These courts will not only support school programming for students but also serve as public resources, fostering interaction among families and youth, helping them build healthy habits that will positively influence their quality of life in the future.
See More
Kailera Therapeutics Makes Successful IPO Amid Biotech Surge
- IPO Pricing and Market Reaction: Kailera Therapeutics priced its initial public offering (IPO) at $16 per share, opening at $26 on April 17; although the stock price has recently cooled, its promising drug pipeline continues to attract investor interest.
- Market Potential Analysis: According to Morgan Stanley research, the GLP-1 drug market aimed at weight loss could reach $190 billion by 2035, doubling the levels of 2025, significantly enhancing Kailera's competitive position in this lucrative market.
- Drug Development Progress: Kailera is building a weight-loss drug pipeline with both injectables and pills, featuring four candidates in various trial stages, with its lead candidate Ribupatide currently in phase 3 trials, potentially becoming a category-leading treatment for obesity.
- Investment Risks and Opportunities: While biotech investments are notoriously risky, Kailera's advanced drug candidates in clinical trials present a fresh investment opportunity, particularly for aggressive investors willing to navigate potential setbacks, as the long-term rewards may outweigh the risks.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
U.S. Healthcare Spending to Exceed $3 Trillion
- Healthcare Spending Surge: The Committee for a Responsible Federal Budget projects U.S. healthcare spending to rise from under $2 trillion today to over $3 trillion in a decade, driven by increased use of GLP-1 drugs, rising cancer diagnoses, and a growing number of chronic health issues, indicating significant investment opportunities in the healthcare sector.
- Pfizer's Outlook: Pfizer (PFE) shares fell 0.81% to $25.75, with a market cap of $147 billion; despite declining demand for its vaccine and Paxlovid, its robust drug pipeline and a forward P/E ratio of 9.0, below the five-year average of 9.7, along with a 6.5% dividend yield, provide investors with a solid income while awaiting growth.
- Intuitive Surgical Investment Potential: Intuitive Surgical (ISRG) shares dropped 1.00% to $427.96, with a market cap of $152 billion; although its forward P/E of 44 is below the five-year average of 55, the high price of its robotic surgery systems and 77% recurring revenue make it a compelling investment choice.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) shares fell 0.87% to $1005.16, with a market cap of $948 billion; its Q1 revenue surged 56% year-over-year to $19.8 billion, with adjusted EPS soaring 156%, driven by strong sales of its GLP-1 weight-loss drugs, suggesting that despite a high stock price, its valuation remains attractive.
See More
Novo Nordisk Aims to Close Gap with Eli Lilly in Weight-Loss Market
- Intensifying Market Competition: Despite Novo Nordisk's first-mover advantage in the weight-loss drug market, Eli Lilly's Zepbound saw an 80% year-over-year sales increase, threatening Novo's market position and prompting the launch of an oral version of Wegovy to cater to patient preferences for oral treatments, thereby enhancing its competitive stance.
- New Drug Development Updates: Eli Lilly launched its own weight-loss pill, Foundayo, in April and is developing a triple agonist, retatrutide, targeting GLP-1, GIP, and glucagon receptors, which could further solidify its market dominance and increase pressure on Novo Nordisk.
- Clinical Trial Results: Eli Lilly's promising phase 3 clinical trial data for retatrutide, released in March, showed significant reductions in A1C and weight loss among participants, establishing a strong foundation for its future market performance and potentially keeping its stock elevated.
- Market Valuation Outlook: Although Eli Lilly's stock trades above $1,000 with a price-to-earnings ratio exceeding 26, if its follow-up products maintain market superiority, investors will likely continue to view it as a top GLP-1 stock, supporting its premium valuation.
See More
Wall Street's Stock Analysis Highlights
- Sell Recommendation for Shutterstock: Shutterstock (SSTK) faces a projected 13.7% sales decline over the next 12 months, with average customer spending down by 87.9%, indicating a challenging demand environment; its earnings per share have fallen by 6.3% annually over the last three years, despite revenue growth, highlighting significantly lower profitability of incremental sales.
- Brookdale's Performance Issues: Brookdale (BKD) has seen flat sales over the past five years, with a projected 4.4% sales drop in the next 12 months; a high net-debt-to-EBITDA ratio of 11x could force the company to raise capital under unfavorable terms if market conditions worsen, with its current stock price at $12.98 and an EV/EBITDA ratio of 15.8.
- Buy Recommendation for Eli Lilly: Eli Lilly (LLY) has achieved an impressive 41.8% annual revenue growth over the past two years, reflecting significant market share gains, while adjusted operating profits and efficiency have improved, and share repurchases have amplified shareholder returns with a 29.6% growth in earnings per share, trading at $990.36 per share with a forward P/E of 26.1.
- Market Sentiment Analysis: While Wall Street's bullish forecasts for several stocks may be overly optimistic, Eli Lilly's strong fundamentals and growth potential position it as a worthy investment, reflecting the market's focus on high-quality companies.
See More
Eli Lilly Provides Community Courts to Indianapolis for 150th Anniversary
- Community Courts Opening: Eli Lilly, in partnership with the Caitlin Clark Foundation, has opened three multi-sport community courts in Indianapolis, aimed at providing safe, high-quality spaces for youth to engage in sports, thereby enhancing community health and vitality.
- Anniversary Contribution: As part of its 150th anniversary celebration, Lilly is providing a park and court at the corner of E. South Street and S. New Jersey Street to the City of Indianapolis and Indy Parks, further solidifying its long-standing connection with the community.
- Facility Design and Features: The newly constructed courts utilize the Musco Mini-Pitch system, designed for basketball, soccer, and futsal, equipped with lighting and ADA-accessible features, ensuring flexible and inclusive spaces for a diverse range of users.
- Long-term Community Impact: These courts will not only support school programming for students but also serve as public resources, fostering interaction among families and youth, helping them build healthy habits that will positively influence their quality of life in the future.
See More
Kailera Therapeutics Makes Successful IPO Amid Biotech Surge
- IPO Pricing and Market Reaction: Kailera Therapeutics priced its initial public offering (IPO) at $16 per share, opening at $26 on April 17; although the stock price has recently cooled, its promising drug pipeline continues to attract investor interest.
- Market Potential Analysis: According to Morgan Stanley research, the GLP-1 drug market aimed at weight loss could reach $190 billion by 2035, doubling the levels of 2025, significantly enhancing Kailera's competitive position in this lucrative market.
- Drug Development Progress: Kailera is building a weight-loss drug pipeline with both injectables and pills, featuring four candidates in various trial stages, with its lead candidate Ribupatide currently in phase 3 trials, potentially becoming a category-leading treatment for obesity.
- Investment Risks and Opportunities: While biotech investments are notoriously risky, Kailera's advanced drug candidates in clinical trials present a fresh investment opportunity, particularly for aggressive investors willing to navigate potential setbacks, as the long-term rewards may outweigh the risks.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
U.S. Healthcare Spending to Exceed $3 Trillion
- Healthcare Spending Surge: The Committee for a Responsible Federal Budget projects U.S. healthcare spending to rise from under $2 trillion today to over $3 trillion in a decade, driven by increased use of GLP-1 drugs, rising cancer diagnoses, and a growing number of chronic health issues, indicating significant investment opportunities in the healthcare sector.
- Pfizer's Outlook: Pfizer (PFE) shares fell 0.81% to $25.75, with a market cap of $147 billion; despite declining demand for its vaccine and Paxlovid, its robust drug pipeline and a forward P/E ratio of 9.0, below the five-year average of 9.7, along with a 6.5% dividend yield, provide investors with a solid income while awaiting growth.
- Intuitive Surgical Investment Potential: Intuitive Surgical (ISRG) shares dropped 1.00% to $427.96, with a market cap of $152 billion; although its forward P/E of 44 is below the five-year average of 55, the high price of its robotic surgery systems and 77% recurring revenue make it a compelling investment choice.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) shares fell 0.87% to $1005.16, with a market cap of $948 billion; its Q1 revenue surged 56% year-over-year to $19.8 billion, with adjusted EPS soaring 156%, driven by strong sales of its GLP-1 weight-loss drugs, suggesting that despite a high stock price, its valuation remains attractive.
See More
